Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by TD Securities to “Hold”

TD Securities lowered shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a buy rating to a hold rating in a research note released on Tuesday,BayStreet.CA reports.

Separately, HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Milestone Pharmaceuticals in a research note on Friday, March 28th.

Milestone Pharmaceuticals Stock Down 5.0 %

NASDAQ MIST opened at $0.76 on Tuesday. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40. Milestone Pharmaceuticals has a 1 year low of $0.72 and a 1 year high of $2.75. The stock has a market capitalization of $40.55 million, a PE ratio of -0.94 and a beta of 1.83. The business’s 50-day moving average is $1.95 and its 200 day moving average is $1.83.

Institutional Trading of Milestone Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of MIST. PVG Asset Management Corp purchased a new position in Milestone Pharmaceuticals during the 3rd quarter valued at approximately $46,000. Jones Financial Companies Lllp lifted its stake in Milestone Pharmaceuticals by 1,000.0% in the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock worth $26,000 after purchasing an additional 10,000 shares during the last quarter. Virtu Financial LLC purchased a new position in Milestone Pharmaceuticals during the 4th quarter valued at $170,000. National Bank of Canada FI increased its stake in Milestone Pharmaceuticals by 163.4% in the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock worth $44,000 after buying an additional 11,600 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Milestone Pharmaceuticals during the fourth quarter valued at approximately $80,000. 86.18% of the stock is currently owned by institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.